chronic-fatigue-syndrome-ResearchAfter the FDA nixed its approval for Ampligen and saddled its producer, Hemispherx Biopharma, with paying for a large new trial, it looked like Ampligen was dead and gone.

Francis Collin’s promise to increase ME/CFS funding, however, caused a seismic shift in the drugs outlook. Hemispherx Biopharma’s board quickly fired its controversial, longtime CEO, William Carter, and appointed Thomas Equels to the post.

In an interview Equels said he had one and only one priority: get FDA approval for Ampligen. Find out more in a Simmaron Research Foundation sponsored post:

New Hemispherx Prez Says Getting Ampligen Approval Top Priority

Print Friendly, PDF & Email

Don't Miss Another Blog!

Like this blog?

Make sure you don’t miss another  one by registering for our free ME/CFS and Fibromyalgia blogs here..

Pin It on Pinterest

Share This